

One Step Multi-Drug, Multi-Line Screen Test Device

Instruction Sheet for testing of any combination of the following drugs: AMP/BZO/COC/THC/mAMP/OPI

A rapid, one step screening test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine.

For Laboratory Use Only.

Catalog# DOA-2165

For in vitro diagnostic use only.

INTENDED USE

The **One Step Multi-Drug, Multi-line Screen Test Device** is a lateral flow chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations:

Test	Calibrator	Cut-off
Amphetamine (AMP)	d-Amphetamine	1,000 ng/mL
Barbiturates (BAR)	Secobarbital	300 ng/mL
Benzodiazepines (BZO)	Oxazepam	300 ng/mL
Cocaine (COC)	Benzoylcegonine	300 ng/mL
Marijuana (THC)	11-nor- Δ^9 -THC-9 COOH	50 ng/mL
Methadone (MTD)	Methadone	300 ng/mL
Methamphetamine (mAMP)	d-Methamphetamine	1,000 ng/mL
Methylenedioxyamphetamin (MDMA)	d,l Methylenedioxyamphetamin	500 ng/mL
Morphine (MOP 300 or OPI 300)	Morphine	300 ng/mL
Opiates (OPI 2000)	Morphine	2,000 ng/mL
Phencyclidine (PCP)	Phencyclidine	25 ng/mL
Tricyclic Antidepressants (TCA)	Nortriptyline	1,000 ng/mL

Configurations of the One Step Multi-Drug, Multi-Line Screen Test Device can consist of any combination of the above listed drug analytes. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

SUMMARY

The **One Step Multi-Drug, Multi-Line Screen Test Device** is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in urine.

AMPHETAMINE (AMP)

Amphetamine is a Schedule II controlled substance available by prescription (Dexedrine®) and is also available on the illicit market. Amphetamines are a class of potent sympathomimetic agents with therapeutic applications. They are chemically related to the human body's natural catecholamines: epinephrine and norepinephrine. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 hours following use and the drug has a half-life of 4-24 hours in the body. About 30% of Amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and deaminated derivatives. The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when Amphetamines in urine exceed 1,000 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).⁴

BARBITURATES (BAR)

Barbiturates are central nervous system depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.

Short acting Barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

Only a small amount (less than 5%) of most Barbiturates are excreted unaltered in the urine.

The approximate detection time limits for Barbiturates are:

Short acting (e.g. Secobarbital) 100 mg PO (oral) 4.5 days

Long acting (e.g. Phenobarbital) 400 mg PO (oral) 7 days¹

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the Barbiturates in urine exceed 300 ng/mL.

BENZODIAZEPINES (BZO)

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, Benzodiazepines have replaced barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal.

Risk of physical dependence increases if Benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Only trace amounts (less than 1%) of most Benzodiazepines are excreted unaltered in the urine; most of the concentration in urine is conjugated drug. The detection period for the Benzodiazepines in the urine is 3-7 days.

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the Benzodiazepines in urine exceed 300 ng/mL.

COCAINE (COC)

Cocaine is a potent central nervous system (CNS) stimulant and a local anesthetic. Initially, it brings about extreme energy and restlessness while gradually resulting in tremors, over-sensitivity and spasms. In large amounts, cocaine causes fever, unresponsiveness, difficulty in breathing and unconsciousness.

Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base smoking. It is excreted in the urine in a short time primarily as Benzoylcegonine.^{2,3} Benzoylcegonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure.³

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the cocaine metabolite in urine exceeds 300 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

MARIJUANA (THC)

THC (Δ^9 -tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered, THC produces euphoric effects. Users have impaired short-term memory and slowed learning. They may also experience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders. The peak effect of marijuana administered by smoking occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolite excreted in the urine is 11-nor- Δ^9 -tetrahydrocannabinol-9-carboxylic acid (Δ^9 -THC-COOH). The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the concentration of THC-COOH in urine exceeds 50 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).⁴

METHADONE (MTD)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, Morphine). The pharmacology of Oral Methadone is very different from IV Methadone. Oral Methadone is partially stored in the liver for later use. IV Methadone acts more like heroin. In most states you must go to a pain clinic or a Methadone maintenance clinic to be prescribed Methadone.

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, Methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from Methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.¹

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the Methadone in urine exceeds 300 ng/mL.

METHAMPHETAMINE (mAMP)

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain. Methamphetamine is closely related chemically to amphetamine, but the central nervous system effects of Methamphetamine are greater. Methamphetamine is made in illegal laboratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Methamphetamine include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, psychotic behavior, and eventually, depression and exhaustion.

The effects of Methamphetamine generally last 2-4 hours and the drug has a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine as amphetamine and oxidized and deaminated derivatives. However, 10-20% of Methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates Methamphetamine use. Methamphetamine is generally detectable in the urine for 3-5 days, depending on urine pH level.

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the Methamphetamine in urine exceeds 1,000 ng/mL.

METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

Methylenedioxyamphetamin (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity.⁹ Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlander, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws. The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the Methylenedioxyamphetamin in urine exceeds 500 ng/mL.

OPIATE (MOP 300)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor.

Opioid analgesics comprise a large group of substances which control pain by depressing the central nervous system. Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose.¹

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the concentration of opiate exceeds the 300 ng/mL cut-off level.

OPIATE (2000)

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the morphine in urine exceeds 2,000 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA). See opiate (MOP 300) for summary.

PHENCYCLIDINE (PCP)

Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations.

Phencyclidine is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter. Phencyclidine is most commonly administered by inhalation but can be used intravenously, intra-nasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the devastating effects of Phencyclidine.

PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days, depending on factors such as metabolic rate, user's age, weight, activity, and diet.⁵ Phencyclidine is excreted in the urine as an unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).⁶

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the phencyclidine level in urine exceeds 25 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

TRICYCLIC ANTIDEPRESSANTS (TCA)

TCA (Tricyclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound central nervous system depression, cardiotoxicity and anticholinergic effects. TCA overdose is the most common cause of death from prescription drugs. TCAs are taken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolites are excreted in urine mostly in the form of metabolites for up to ten days.

The **One Step Multi-Drug, Multi-Line Screen Test Device** yields a positive result when the concentration of Tricyclic Antidepressants in urine exceeds 1,000 ng/mL.

PRINCIPLE

The **One Step Multi-Drug, Multi-Line Screen Test Device** is an immunoassay based on the principle of competitive binding. Drugs, which may be present in the urine specimen, compete against their respective drug conjugate for binding sites on their specific antibody.

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region.

A drug-positive urine specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative urine specimen will generate a line in the test line region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

REAGENTS

Each test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. Control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG.

PRECAUTIONS

- For healthcare professionals including professionals at point of care sites.
- For *in vitro* diagnostic use only.
- Do not use after the expiration date.
- The test device should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test device should be discarded according to federal, state and local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 2-30°C. The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear supernatant for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing.

MATERIALS

Materials Provided

- Test devices
- Disposable droppers
- Package insert


Materials Required But Not Provided

- Specimen collection container
- External controls
- Timer

DIRECTIONS FOR USE

Allow the test device, urine specimen, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

- Remove the test device from the sealed pouch and use it as soon as possible.
- Place the test device on a clean and level surface. Hold the dropper vertically and transfer 3 full drops of urine (approx. 100 ul total volume) to the specimen well (S) of the test device, and then start the timer. Avoid trapping air bubbles in the specimen well (S). See the illustration below.
- Wait for the colored lines(s) to appear. The results should be read at 5 minutes or up to 4 hours after test initiation.



(Please refer to the illustration above)

POSITIVE: No line appears in the Test region (T) for a specific drug tested. One colored line appears in the Control region (C). The positive result indicates that the drug concentration in the urine sample exceeds the designated cut-off for a specific drug.

NEGATIVE: The appearance of a colored line in C region and a colored line in the T region for a specific drug indicate a negative test result. Up to four colored lines may appear: one line in the C region, and up to three lines in the T region. This negative result indicates that the drug concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.

***NOTE:** The shade of color in the test region (T) may vary, but it should be considered negative whenever

there is even a faint line.

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for Control line failure. Review the procedure and repeat the test with a new test device. If the problem persists, contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A colored line appearing in the Control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

- The **One Step Multi-Drug, Multi-Line Screen Test Device** provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.^{3,4,7}
- There is a possibility that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.
- Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- A Positive result does not indicate level of intoxication, administration route or concentration in urine.
- A Negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- Test does not distinguish between drugs of abuse and certain medications.
- A positive test result might be obtained from certain foods or food supplements.

PERFORMANCE CHARACTERISTICS

Accuracy

A side-by-side comparison was conducted using the **One Step Multi-Drug, Multi-Line Screen Test Device** and commercially available drug rapid tests. Testing was performed on approximately 1,000 specimens previously collected from subjects presenting for Drug Screen Testing. Some specimens in the +/- 25% cut-off levels were prepared by diluting from the more concentrated clinical specimens with the neat urine. Presumptive positive results were confirmed by GC/MS. Negative urine samples were screened initially by Predicate test. Approximately 10% negative samples were confirmed by GC/MS. The following compounds were quantified by GC/MS and contributed to the total amount of drugs found in presumptive positive urine samples tested in the following clinical studies:

Test	Compounds Contributed to the Totals of GC/MS
AMP	Amphetamine
BAR	Secobarbital, Butalbital, Phenobarbital, Pentobarbital
BZO	Oxazepam, Nordiazepam, OH-Alprazolam, Desalkylflurazepam
COC	Benzoylcegonine
THC	11-nor- Δ^9 -tetrahydrocannabinol-9-carboxylic acid
MTD	Methadone
mAMP	Methamphetamine
MDMA	d,l Methylendioxyamphetamine
OPI	Morphine, Codeine
PCP	Phencyclidine
TCA	Nortriptyline

The following results were tabulated:

Method	GC/MS						
	Neg. *	Neg. (< -25% cutoff)	Near cutoff neg. (-25% cutoff to cutoff)	Near cutoff pos. (cutoff to +25% cutoff)	Pos. (> +25% cutoff)	% agreement with GC/MS	
AMP	Positive	0	0	1	14	114	94%
	Negative	150	2	12	8	0	99%
BAR	Positive	0	0	2	4	118	92
	Negative	150	2	6	1	10	99
BZO	Positive	0	2	0	6	122	98
	Negative	150	9	2	2	1	98
COC	Positive	0	0	1	13	99	95%
	Negative	150	8	22	4	2	99%
THC	Positive	0	5	3	12	114	95%
	Negative	150	14	6	2	4	95%

MTD	Positive	0	0	0	2	118	93
	Negative	150	17	10	8	1	>99
mAMP	Positive	0	0	0	4	116	90%
	Negative	150	0	12	6	8	>99%
MDMA	Positive	0	0	3	6	79	98
	Negative	150	0	2	0	2	98
MOP	Positive	0	1	4	4	115	98
	Negative	150	2	3	2	1	97
OPI	Positive	0	0	2	19	111	98%
	Negative	150	0	14	1	1	99%
PCP	Positive	0	0	2	6	64	90%
	Negative	150	0	2	3	5	99%
TCA**	Positive	0	9	2	14	20	>99
	Negative	150	24	7	0	0	94

*Negative urine samples were screened by predicate tests.

**Note: TCA concentration was based on HPLC data.

Method	Predicate Test Results		% Agreement with Predicate Test	
	Positive	Negative		
AMP	Positive	129	0	>99
	Negative	0	172	>99
BAR	Positive	124	0	98
	Negative	2	167	>99
BZO	Positive	130	0	98
	Negative	2	162	>99
COC	Positive	112	1	>99
	Negative	0	186	99
THC	Positive	124	0	>99
	Negative	0	176	>99
MTD	Positive	120	0	87
	Negative	18	168	>99
mAMP	Positive	121	0	>99
	Negative	0	172	>99
MDMA	Positive	88	0	97
	Negative	2	152	>99
MOP	Positive	124	0	94
	Negative	8	150	>99
OPI	Positive	132	0	99
	Negative	1	164	>99
PCP	Positive	72	0	>99
	Negative	0	160	>99
TCA	Positive	45	0	92
	Negative	4	177	>99

Analytical Sensitivity

A drug-free urine pool was spiked with drugs to the concentrations at \pm 50% cut-off and \pm 25% cut-off. The results are summarized below.

Drug Conc. (Cut-off range)	n	AMP		BAR		BZO	
		-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0
-25% Cut-off	30	26	4	23	7	24	6
Cut-off	30	23	7	14	16	15	15
+25% Cut-off	30	7	23	7	23	6	24
+50% Cut-off	30	0	30	0	30	0	30

Drug Conc. (Cut-off range)	n	COC		THC		MTD	
		-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0
-25% Cut-off	30	25	5	24	6	26	4
Cut-off	30	20	10	15	15	13	17
+25% Cut-off	30	5	25	6	24	5	25
+50% Cut-off	0	0	30	0	30	0	30

Drug Conc. (Cut-off range)	n	mAMP		MDMA		MOP	
		-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0
-25% Cut-off	30	25	5	27	3	20	10
Cut-off	30	23	7	17	13	18	12
+25% Cut-off	30	6	24	6	24	7	23
+50% Cut-off	0	0	30	0	30	0	30

Drug Conc. (Cut-off range)	n	OPI		PCP		TCA	
		-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0
-25% Cut-off	30	26	4	26	4	25	2
Cut-off	30	11	19	19	11	13	17
+25% Cut-off	30	5	25	5	25	7	23
+50% Cut-off	0	0	30	0	30	0	30

Eighty (80) of these samples for each drug test were also run using ACON's multi-drug test device by an untrained operator at a physician's office. Based on GC/MS data, the operator obtained a statistically similar positive agreement, negative agreement and overall agreement rate as the laboratory personnel.

Analytical Specificity

The following table lists the concentration of compounds (ng/mL) that are detected positive in urine by the One Step Multi-Drug, Multi-Line Screen Test Device at 5 minutes.

AMPHETAMINE	ng/mL
d-Amphetamine	1,000
d,l-Amphetamine sulfate	3,000
l-Amphetamine	50,000
(±)3,4-Methylenedioxyamphetamine	2,000
Phentermine	3,000
BARBITURATES	
Secobarbital	300
Amobarbital	300
Alphenol	150
Aprobarbital	200
Butabarbital	75
Butalbital	2,500
Butethal	100
Cyclopentobarbital	600
Pentobarbital	300
Phenobarbital	100
BENZODIAZEPINES	
Oxazepam	300
Alprazolam	196
a-Hydroxyalprazolam	1,262
Bromazepam	1,562
Chlordiazepoxide	1,562
Chlordiazepoxide	781
Clobazam	98
Clonazepam	781
Clorazepate dipotassium	195
Delorazepam	1,562
Desalkylflurazepam	390

Diazepam	195
Estazolam	2,500
Flunitrazepam	390
(±) Lorazepam	1,562
RS-Lorazepam glucuronide	156
Midazolam	12,500
Nitrazepam	98
Norchlordiazepoxide	195
Nordiazepam	390
Temazepam	98
Triazolam	2,500
COCAINE	
Benzoylcegonine	300
Cocaine	780
Cocaethylene	12,500
Ecgonine	32,000

MARIJUANA (THC)

11-nor- Δ^9 -THC-9 COOH	50
Cannabinol	20,000
11-nor- Δ^8 -THC-9 COOH	30
Δ^8 -THC	15,000
Δ^9 -THC	15,000

METHADONE

Methadone	300
Doxylamine	50,000

METHAMPHETAMINE

d-Methamphetamine	1,000
p-Hydroxymethamphetamine	30,000
l-Methamphetamine	8,000
(±)-3,4-Methylenedioxymethamphetamine	2,000
Mephentermine	50,000

METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

d,l-3,4-Methylenedioxymethamphetamine (MDMA)	500
3,4-Methylenedioxyamphetamine (MDA)	3,000
3,4-Methylenedioxyethyl-amphetamine (MDE)	300

OPIATE 300 (MOP)

Morphine	300
Codeine	300
Ethylmorphine	6,250
Hydrocodone	50,000
Hydromorphone	3,125
Levorphanol	1500
6-Monoacetylmorphine	400
Morphine 3- β -D-glucuronide	1,000
Norcodeine	6,250
Normorphine	100,000
Oxycodone	30,000

Oxymorphone	100,000
Procaine	15,000
Thebaine	6,250
OPIATES (2000)	
Morphine	2,000
Codeine	2,000
Ethylmorphine	5,000
Hydrocodone	12,500
Hydromorphone	5,000
Levophanol	75,000
6-Monoacetylmorphine	5,000
Morphine 3- β -D-glucuronide	2,000
Norcodeine	12,500
Normorphine	50,000
Oxycodone	25,000
Oxymorphone	25,000
Procaine	150,000
Thebaine	100,000

PHENCYCLINDE (PCP)

Phencyclidine	25
4-Hydroxyphencyclidine	12,500

TRICYCLIC ANTIDEPRESSANTS (TCA)

Notriptyline	1,000
Nordoxepin	1,000
Trimipramine	3,000
Amitriptyline	1,500
Promazine	1,500
Desipramine	200
Imipramine	400
Clomipramine	12,500
Doxepin	2,000
Maprotiline	2,000
Promethazine	25,000

Precision

A study was conducted at three physician offices for Amphetamine, Cocaine, Marijuana, Methamphetamine, Opiate and Phencyclidine by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens, containing drugs at the concentration of $\pm 50\%$ and $\pm 25\%$ cut-off level, was labeled as a blind and tested at each site. The results are given below:

Drug Conc.	n per site	Site A		Site B		Site C	
		-	+	-	+	-	+
Negative	90	90	0	90	0	90	0
-50% Cut-off	90	90	0	88	2	89	1
-25% Cut-off	90	80	10	70	20	70	20
+25% Cut-off	90	34	56	13	77	12	78
+50% Cut-off	90	5	85	5	85	3	87

A study was conducted at three physician offices for Barbiturates, Benzodiazepines, Methadone, Methylenedioxymethamphetamine, Morphine, and Tricyclic Antidepressants by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens, containing drugs at the concentration of $\pm 50\%$ and $\pm 25\%$ cut-off level, was labeled as a blind and tested at each site. The results are given below:

Drug Conc.	n per site	Site A		Site B		Site C	
		-	+	-	+	-	+
Negative	90	90	0	90	0	90	0
-50% Cut-off	90	83	7	87	3	90	0
-25% Cut-off	90	67	23	75	15	80	10
+25% Cut-off	90	28	62	30	60	22	68
+50% Cut-off	90	1	89	0	90	2	88

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.000-1.037) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The One Step Multi-Drug, Multi-Line Screen Test Device was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity does not affect the test results.

Effect of the Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the One Step Multi-Drug, Multi-Line Screen Test Device. The results demonstrate that varying ranges of pH does not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or Cocaine, Amphetamine, Methamphetamine, Marijuana, Opiate or Phencyclidine positive urine. The following compounds show no cross-reactivity when tested with the One Step Multi-Drug, Multi-Line Screen Test Device at a concentration of 100 $\mu\text{g/mL}$.

Non Cross-Reacting Compounds

Acetaminophen	Acetophenetidin
N-Acetylprocainamide	Acetylsalicylic acid
Aminopyrine	Amoxicillin
Ampicillin	l-Ascorbic acid
Apomorphine	Aspartame
Atropine	Benzilic acid
Benzoic acid	Benzphetamine*
Bilirubin	d/l-Brompheniramine
Caffeine	Cannabidiol
Chloralhydrate	Chloramphenicol
Chlorothiazide	d/l-Chloropheniramine
Chlorpromazine	Chloroquine
Cholesterol	Clonidine
Cortisone	l-Cotinine
Creatinine	Deoxycorticosterone
Dextromethorphan	Diclofenac
Diflunisal	Digoxin
Diphenhydramine	Ecgonine methyl ester
l- Ψ -Ephedrine	β -Estradiol
Estrone-3-sulfate	Ethyl-p-aminobenzoate
[1R,2S] (-) Ephedrine	l(-)-Epinephrine
Erythromycin	Fenoprofen
Furosemide	Gentisic acid

Hemoglobin	Hydralazine
Hydrochlorothiazide	Hydrocortisone
o-Hydroxyhippuric acid	p-Hydroxyamphetamine
p-Hydroxytyramine	Ibuprofen
lproniazid	d/l-Isoproterenol
Isoxsuprine	Ketamine
Ketoprofen	Labetalol
Loperamide	Meperidine
Meprobamate	Methoxyphenamine
Methylphenidate	Nalidixic acid
Naloxone	Naltrexone
Naproxen	Niacinamide
Nifedipine	Norethindrone
d-Norpropoxyphene	Noscapine
d/l-Octopamine	Oxalic acid
Oxolinic acid	Oxymetazoline
Papaverine	Penicillin-G
Pentazocine hydrochloride	Perphenazine
Phenelzine	Trans-2-phenylcyclo-propylamine hydrochloride
l-Phenylephrine	β -Phenylethylamine
Phenylpropanolamine	Prednisolone
Prednisone	d/l-Propranolol
d-Propoxyphene	d-Pseudoephedrine
Quinacrine	Quinine
Quindine	Ranitidine
Salicylic acid	Serotonin
Sulfamethazine	Sulindac
Tetracycline	Tetrahydrocortisone 3-acetate
Tetrahydrocortisone 3 (β -D-glucuronide)	Tetrahydrozoline
Thiamine	Thioridazine
d/l-Tyrosine	Tolbutamide
Triamterene	Trifluoperazine
Trimethoprim	Tryptamine
d/l-Tryptophan	Tyramine
Uric acid	Verapamil
Zomepirac	

*Parent compound only; metabolizes into amphetamine and methamphetamine in the body.

BIBLIOGRAPHY

1. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735.
2. Stewart DJ, Inaba T, Lucassen M, Kalow W. *Clin. Pharmacol. Ther.* April 1979; 25 ed: 464, 264-8.
3. Ambre J. *J. Anal. Toxicol.* 1985; 9:241.
4. Hawks RL, CN Chiang. *Urine Testing for Drugs of Abuse*. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986.
5. FDA Guidance Document: Guidance for Premarket Submission for Kits for Screening Drugs of Abuse to be Used by the Consumer, 1997.
6. Robert DeCresce. *Drug Testing in the workplace*, 114.
7. Baselt RC. *Disposition of Toxic Drugs and Chemicals in Man*. 2nd Ed. Biomedical Publ., Davis, CA 1982; 487.
8. Winger, Gail, A Handbook of Drug and Alcohol Abuse, Third Edition, Oxford Press, 1992, page 146.

DN: DOA-2165

Rev. Date: Sept 20 2010



NOVA CENTURY SCIENTIFIC

Nova Century Scientific
5022 South Service Road
Burlington, Ontario L7L 5Y7
Tel: 1-800-615-5072
Fax: 1-800-639-9006
www.novacentury.com